Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

Innovations Proteomics Brings to Cancer Diagnosis and Treatment

Innovations Proteomics Brings to Cancer Diagnosis and Treatment

Cancer is not only a genetic disease at the “cellular” level but also a proteomic disease. Disrupted protein structures impair important pathways and cause cancer. Proteomics studies proteins, more functionally active than genes, and offers hope for effective treatments and early diagnosis.

Recent proteomic research focuses on;

1. Discovering Rare Cancer Proteins: Failure to discover suitable biomarkers is the main reason for late diagnosis. Proteomics uses a system called mass spectrometry to identify proteins by analyzing mass. Research aims to detect cancer-causing proteins even in very small amounts. Traditional methods cannot identify these rare proteins at an early stage of disease.

Recent research seeks to detect HER2/neu in blood. Her2/neu is a growth factor particularly active in breast cancer. Drugs targeting it have been designed and are actively used. It is also highly active in 30 percent of breast, ovarian and pancreatic tumors. Usually, HER2/neu becomes detectable only after the tumor reaches a certain growth capacity. Using mass spectrometry, researchers successfully diagnosed cancer “at an early stage” in laboratory mice. Early-detected mouse cancers could be treated with targeted drugs, preventing visible tumor recurrence. Researchers aim to detect this protein from very small human blood samples in the near future.

2. Human Proteome Project: Mapping our entire genome took approximately 12 years. We have 22 thousand genes and 3 billion bases. Because proteins are more complex, mapping them will take longer. The human body has over 500.000 protein types. The proteome (all human proteins) has begun to be mapped. This project aims to reveal proteins' disease roles. Its cancer importance is discovering cancer-causing oncoproteins and enabling drug development.

3. Tumor Dormancy Research: As previously discussed, dormant cancer cells are a major cause of recurrence. How and when tumors become dormant remains unknown, but proteomics is advancing understanding. For example, certain proteins in blood platelets (thrombocytes) may provide information about dormant cancer cells.

In conclusion, proteomics has begun serving as a new “supporting” cancer research discipline. Soon it may clarify proteins' role in cancer and enable effective treatment design. Mass spectrometry may also determine “rapidly and in real time” whether biopsy tissue contains cancer cells.

Sources

1. Human Protein Atlas,2016

2. Koomen, J. M., Haura, E. B., Bepler, G.
Proteomic Contributions to Personalized Cancer Care.
Molecular & Cellular Proteomics (2008) MCP, 7(10), 1780–1794.

3. Almog, N., & Klement, G. L.
Platelet Proteome and Tumor Dormancy: Can Platelets Content Serve as Predictive Biomarkers for Exit of Tumors from Dormancy?
Cancers, (2010). 2(2), 842–858.

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

Innovations Proteomics Brings to Cancer Diagnosis and Treatment

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy